Compass therapeutics to host webcast highlighting top-line clinical data from the ongoing randomized phase 2/3 study evaluating tovecimig in patients with biliary tract cancer

Webcast scheduled for tuesday, april 1, 2025 at 8:00 am et. boston, march 31, 2025 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on tuesday, april 1, 2025 at 8:00 am et to review top-line clinical data from its ongoing phase 2/3 companion-002 clinical trial assessing tovecimig (a dll4 x vegf-a bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (btc).
CMPX Ratings Summary
CMPX Quant Ranking